Current best practices and rationalistic perspectives in causation-based prevention, early detection and multidisciplinary treatment of breast and gastric cancer

Gastric & Breast Cancer e-journal
DOI: 10.2122/gbc.2011.0189


KRAS mutation testing: Why is it now not recommended for colorectal cancer EGFR inhibitors treatment decision?

Prof. Dr. Albrecht Encke, MD, PhD.

Affiliation: Prof. Dr. Albrecht Encke, Direktor der Chirurgische Universitätsklinik Frankfurt/Main, Theodor Stern Kai 7, 60590 Frankfurt/Main, Germany.

E-mail :

Since there is no abstract available we provide the first paragraph

Mutation testing for identifying mutations in KRAS gene has become a standard for patients with advanced colorectal cancer for deciding on cetuximab. However, evidence is insufficient to support this approach. Two phase 3 trials accurately designed in the early and advanced colorectal cancer setting change this strategy. Why such a mutation testing cannot provide clinical utility and how can be explained the up and down of KRAS mutational status as predictive biomarker?

(Citation: Gastric & Breast Cancer 2011; 10(4) 220-222)

You can have an online full-text access and a PDF of this article:
  • Either purchase this paper for €33 EUR. Please, click here
Please specify DOI of article
  • Or through one year subscription PayPal

Online ISSN : 1109 - 7647
Print ISSN : 1109 - 7655

We subscribe to the HONcode principles of the HON Foundation. Click to verify. We subscribe to the HONcode principles. Verify here.
please, read our policy about privacy and confidentiality of information and transparency of sponsorship

last update: 9 September 2011